Against the backdrop of sustained growth in the global peptide drug industry, and steadily increasing global client demand for GLP-1-class peptides, peptide-drug conjugates (PDCs), peptide CDMO services, and related capabilities, JYMed Peptides (hereinafter referred...
The peptide sector is undergoing a profound transformation. In the early days, the core question from clients was, “Can it be made?” Today, as GLP-1 therapies and other innovative peptide drugs enter large-scale commercialization, pharmaceutical companies are looking...
JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process. FDA acknowledgment letter for JYMed’s Type II DMF filing for semaglutide API...
Why Sustainable Peptide Manufacturing Is Becoming Essential in Pharma Sustainable peptide manufacturing is rapidly becoming a priority in the pharmaceutical industry. The rapid global expansion of peptide therapeutics in metabolic and chronic disease treatment is...
Innovation at the Core of Peptide Manufacturing Advanced peptide synthesis technologies are essential to meeting the growing demand for complex peptides in metabolic, oncological, and cosmetic therapeutics. Achieving reliable and scalable production requires mastery...
How JYMed Delivers Integrated, cGMP-Compliant Peptide CDMO Solutions from Discovery to Delivery Introduction: The Critical Role of Peptides in Modern Therapeutics Peptides are reshaping the pharmaceutical landscape, driving innovation across metabolic therapies,...
中文
